Matthew Loxton
Healthcare improvement and strategic foresight analyst, professional trainer in qualitative research methods. Organizational behavior researcher. Board member at Blue Faery Liver Cancer. #Writer of stuff - #AmWriting
Read my #fiction titles on Amazon “The Screw Turns” at https://www.amazon.com/stores/author/B09P5LLNZ1
See my Kindle Vela stories at https://www.amazon.com/kindle-vella/story/B0BLXHVVSY
… and my children’s stories at https://www.amazon.com/kindle-vella/story/B0BLT56MG9
- 0 Posts
- 2 Comments
Joined 2 years ago
Cake day: November 8th, 2022
You are not logged in. If you use a Fediverse account that is able to follow users, you can follow this user.
@[email protected]
I think I know the answer to the main question, and it is a bit boring.
I expect that Neuralink got approval for human testing because they used a “same as” application, and could cite many other very similar implants that had been previously approved for other applicants. (2002, 2006, etc)
I want to know how this patient selected, the end points, what is this “issue” that the patient mentioned, what outcomes and adverse effects are being monitored, what are the rollback options?